Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
- 4 September 2024
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 96 (4) , 361-369
Abstract
Background Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, pConclusion Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.Keywords
This publication has 40 references indexed in Scilit:
- Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGADAnnals of Neurology, 2024
- A comprehensive review of the advances in neuromyelitis optica spectrum disorderAutoimmunity Reviews, 2023
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term managementJournal of Neurology, 2023
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosisJournal of Neurology, 2023
- Aquaporin‐4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with ImmunosuppressantsAnnals of Neurology, 2023
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum DisorderJAMA Network Open, 2022
- Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohortActa Neurologica Belgica, 2021
- Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trialJournal of Neurology, 2017
- Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis OpticaJAMA Neurology, 2014
- Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse MyelitisArchives of Neurology, 2008